BrainsWay Ltd. is a commercial stage medical device company. It is focused on the development and sale of non-invasive neuromodulation products using the Company's proprietary Deep Transcranial Magnetic Stimulation technology for the treatment of major depressive disorder and obsessive-compulsive disorder. BrainsWay Ltd. is based in Jerusalem, Israel.
| Revenue (Most Recent Fiscal Year) | $41.02M |
| Net Income (Most Recent Fiscal Year) | $2.92M |
| PE Ratio (Current Year Earnings Estimate) | 42.68 |
| PE Ratio (Trailing 12 Months) | 58.00 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 6.22 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.18 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 60.47 |
| Pre-Tax Margin (Trailing 12 Months) | 12.66% |
| Net Margin (Trailing 12 Months) | 11.60% |
| Return on Equity (Trailing 12 Months) | 8.97% |
| Return on Assets (Trailing 12 Months) | 5.65% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.51 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.34 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 2.77 |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.31 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.10 |
| Earnings per Share (Most Recent Fiscal Year) | $0.18 |
| Diluted Earnings per Share (Trailing 12 Months) | $0.26 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Common Shares Outstanding | 19.00M |
| Free Float | 15.39M |
| Market Capitalization | $286.58M |
| Average Volume (Last 20 Days) | 0.06M |
| Beta (Past 60 Months) | 1.23 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 19.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 30.11% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |